Sosne, G.; Kleinman, H.K.; Springs, C.; Gross, R.H.; Sung, J.; Kang, S.
0.1% RGN-259 (Thymosin ß4) Ophthalmic Solution Promotes Healing and Improves Comfort in Neurotrophic Keratopathy Patients in a Randomized, Placebo-Controlled, Double-Masked Phase III Clinical Trial. Int. J. Mol. Sci. 2023, 24, 554.
https://doi.org/10.3390/ijms24010554
AMA Style
Sosne G, Kleinman HK, Springs C, Gross RH, Sung J, Kang S.
0.1% RGN-259 (Thymosin ß4) Ophthalmic Solution Promotes Healing and Improves Comfort in Neurotrophic Keratopathy Patients in a Randomized, Placebo-Controlled, Double-Masked Phase III Clinical Trial. International Journal of Molecular Sciences. 2023; 24(1):554.
https://doi.org/10.3390/ijms24010554
Chicago/Turabian Style
Sosne, Gabriel, Hynda K. Kleinman, Clark Springs, Robert Hollis Gross, Jihye Sung, and Shinwook Kang.
2023. "0.1% RGN-259 (Thymosin ß4) Ophthalmic Solution Promotes Healing and Improves Comfort in Neurotrophic Keratopathy Patients in a Randomized, Placebo-Controlled, Double-Masked Phase III Clinical Trial" International Journal of Molecular Sciences 24, no. 1: 554.
https://doi.org/10.3390/ijms24010554
APA Style
Sosne, G., Kleinman, H. K., Springs, C., Gross, R. H., Sung, J., & Kang, S.
(2023). 0.1% RGN-259 (Thymosin ß4) Ophthalmic Solution Promotes Healing and Improves Comfort in Neurotrophic Keratopathy Patients in a Randomized, Placebo-Controlled, Double-Masked Phase III Clinical Trial. International Journal of Molecular Sciences, 24(1), 554.
https://doi.org/10.3390/ijms24010554
